Castle Biosciences
(NASDAQ) CSTL
Castle Biosciences Financials at a Glance
Market Cap
$700.17M
Revenue (TTM)
$344.23M
Net Income (TTM)
$24.16M
EPS (TTM)
$-0.85
P/E Ratio
-27.80
Dividend
$0.00
Beta (Volatility)
1.48 (Average)
Dividend
$0.00
Beta (Volatility)
1.48 (Average)
Price
$23.59
Volume
10,812
Open
$23.55
Price
$23.59
Volume
10,812
Open
$23.55
Previous Close
$23.59
Daily Range
$23.23 - $23.94
52-Week Range
$14.59 - $44.28
Dividend
$0.00
Beta (Volatility)
1.48 (Average)
Price
$23.59
Volume
10,812
Open
$23.55
Previous Close
$23.59
Daily Range
$23.23 - $23.94
52-Week Range
$14.59 - $44.28
CSTL News
CSTL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Castle Biosciences
Industry
Healthcare Providers and Services
Sector
Health CareEmployees
883
CEO
Derek J. Maetzold
Website
www.castlebiosciences.comHeadquarters
Friendswood, TX 77546, US
CSTL Financials
Key Financial Metrics (TTM)
Gross Margin
69%
Operating Margin
-12%
Net Income Margin
-7%
Return on Equity
-5%
Return on Capital
-8%
Return on Assets
-4%
Earnings Yield
-3.60%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$700.17M
Shares Outstanding
29.73M
Volume
10.81K
Short Interest
0.00%
Avg. Volume
403.77K
Financials (TTM)
Gross Profit
$236.35M
Operating Income
$42.81M
EBITDA
$11.34M
Operating Cash Flow
$64.35M
Capital Expenditure
$36.02M
Free Cash Flow
$28.33M
Cash & ST Invst.
$299.50M
Total Debt
$36.91M
Castle Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$87.01M
+0.8%
Gross Profit
$31.84M
-54.6%
Gross Margin
36.59%
N/A
Market Cap
$700.17M
N/A
Market Cap/Employee
$893.07K
N/A
Employees
784
N/A
Net Income
$2.33M
-124.3%
EBITDA
$1.09M
-92.1%
Quarterly Fundamentals
Net Cash
$262.59M
-1.6%
Accounts Receivable
$43.38M
-15.3%
Inventory
$10.25M
+26.0%
Long Term Debt
$35.17M
+44.1%
Short Term Debt
$1.74M
-10.3%
Return on Assets
-4.18%
N/A
Return on Invested Capital
-8.40%
N/A
Free Cash Flow
$19.75M
+17.6%
Operating Cash Flow
$26.93M
+10.5%